MX364864B - Microesferas o microparticulas biodegradables o bioerosionables de liberacion progresiva suspendidas en una formulacion de farmaco inyectable de formacion de deposito solidificante. - Google Patents

Microesferas o microparticulas biodegradables o bioerosionables de liberacion progresiva suspendidas en una formulacion de farmaco inyectable de formacion de deposito solidificante.

Info

Publication number
MX364864B
MX364864B MX2014008857A MX2014008857A MX364864B MX 364864 B MX364864 B MX 364864B MX 2014008857 A MX2014008857 A MX 2014008857A MX 2014008857 A MX2014008857 A MX 2014008857A MX 364864 B MX364864 B MX 364864B
Authority
MX
Mexico
Prior art keywords
drug formulation
injectable drug
time released
depot
microparticles suspended
Prior art date
Application number
MX2014008857A
Other languages
English (en)
Other versions
MX2014008857A (es
Inventor
A Marsh David
Ma Rivers Hongwen
Original Assignee
Allergan Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Allergan Inc filed Critical Allergan Inc
Publication of MX2014008857A publication Critical patent/MX2014008857A/es
Publication of MX364864B publication Critical patent/MX364864B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A61K9/0051—Ocular inserts, ocular implants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents

Abstract

Se puede inyectar un material de administración de fármacos compuesto en un ojo de un ser humano o mamífero para proporcionar la liberación progresiva del fármaco. Un material de administración de fármacos compuesto puede incluir diversas macropartículas dispersadas en una composición de medios. Las micropartículas pueden contener un fármaco y un recubrimiento que comprende un material bioerosionable o un material biodegradable y la composición de medios incluye el fármaco dispersado en un material de formación de depósito. La composición de medios se puede gelificar o solidificar después de la inyección en el ojo.
MX2014008857A 2012-01-23 2013-01-22 Microesferas o microparticulas biodegradables o bioerosionables de liberacion progresiva suspendidas en una formulacion de farmaco inyectable de formacion de deposito solidificante. MX364864B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261589681P 2012-01-23 2012-01-23
PCT/US2013/022466 WO2013112434A1 (en) 2012-01-23 2013-01-22 Time released biodegradable or bioerodible microspheres or microparticles suspended in a solidifying depot-forming injectable drug formulation

Publications (2)

Publication Number Publication Date
MX2014008857A MX2014008857A (es) 2015-07-17
MX364864B true MX364864B (es) 2019-05-09

Family

ID=47630595

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2014008857A MX364864B (es) 2012-01-23 2013-01-22 Microesferas o microparticulas biodegradables o bioerosionables de liberacion progresiva suspendidas en una formulacion de farmaco inyectable de formacion de deposito solidificante.

Country Status (18)

Country Link
US (3) US20130189369A1 (es)
EP (1) EP2806853B1 (es)
JP (1) JP6282231B2 (es)
KR (5) KR20140114892A (es)
CN (1) CN104136006B (es)
AU (3) AU2013212583A1 (es)
BR (1) BR112014017969A8 (es)
CA (1) CA2861348C (es)
DK (1) DK2806853T3 (es)
ES (1) ES2821526T3 (es)
HK (1) HK1204765A1 (es)
HU (1) HUE050904T2 (es)
IL (2) IL233620A0 (es)
MX (1) MX364864B (es)
NZ (1) NZ627368A (es)
RU (1) RU2672596C2 (es)
WO (1) WO2013112434A1 (es)
ZA (1) ZA201405091B (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150335704A1 (en) * 2014-05-23 2015-11-26 Imprimis Pharmaceuticals, Inc. Pharmaceutical compositions comprising gels and methods for fabricating thereof
US20170112936A1 (en) * 2014-05-23 2017-04-27 Imprimis Pharmaceuticals, Inc. Pharmaceutical compositions comprising gels and methods for fabricating thereof
CN104306330A (zh) * 2014-09-24 2015-01-28 万特制药(海南)有限公司 一种盐酸美金刚缓释混悬液及其制备方法
WO2017053346A1 (en) 2015-09-21 2017-03-30 Teva Pharmaceuticals International Gmbh Sustained release olanzapine formulations
SG11201803663XA (en) 2015-11-12 2018-05-30 Graybug Vision Inc Aggregating microparticles for therapy
US10682340B2 (en) 2016-06-30 2020-06-16 Durect Corporation Depot formulations
JP7051721B2 (ja) 2016-06-30 2022-04-11 デュレクト コーポレーション デポー製剤
CA3057438A1 (en) 2017-03-20 2018-09-27 Teva Pharmaceuticals International Gmbh Sustained release olanzapine formulaitons
CN111201040A (zh) 2017-05-10 2020-05-26 灰色视觉公司 用于医学疗法的缓释微粒及其悬浮液
JP2020531571A (ja) * 2017-07-11 2020-11-05 サステインドナノシステムズエルエルシーＳｕｓｔａｉｎｅｄ Ｎａｎｏ Ｓｙｓｔｅｍｓ Ｌｌｃ 超圧縮医薬製剤
CN107595765A (zh) * 2017-09-22 2018-01-19 沈阳兴齐眼药股份有限公司 一种眼用缓释药物递送系统及其制备方法
GB2586975B (en) * 2019-09-09 2024-03-06 Roemex Ltd Device and method for use with subsea pipelines
US20240100012A1 (en) 2021-01-18 2024-03-28 Mark Hasleton Pharmaceutical dosage form
WO2022198167A1 (en) * 2021-03-15 2022-09-22 Oakwood Laboratories, Llc Microsphere formulations comprising naltrexone and methods for making and using the same
WO2023281406A1 (en) 2021-07-06 2023-01-12 Mark Hasleton Treatment of serotonin reuptake inhibitor withdrawal syndrome

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5252318A (en) * 1990-06-15 1993-10-12 Allergan, Inc. Reversible gelation compositions and methods of use
DE69524398T2 (de) * 1994-04-08 2002-07-18 Atrix Lab Inc Flüssige mittel zur wirkstoffabgabe
AU739469B2 (en) * 1996-12-20 2001-10-11 Alza Corporation Gel composition and methods
US6589549B2 (en) * 2000-04-27 2003-07-08 Macromed, Incorporated Bioactive agent delivering system comprised of microparticles within a biodegradable to improve release profiles
GB0122318D0 (en) * 2001-09-14 2001-11-07 Novartis Ag Organic compounds
US20070196415A1 (en) * 2002-11-14 2007-08-23 Guohua Chen Depot compositions with multiple drug release rate controls and uses thereof
CN1314452C (zh) * 2002-04-22 2007-05-09 沈阳药科大学 具有适宜相转变温度的眼用原位凝胶制剂
CN100453066C (zh) * 2002-12-04 2009-01-21 参天制药株式会社 利用结膜下储存库的药物释放系统
US20090148527A1 (en) * 2007-12-07 2009-06-11 Robinson Michael R Intraocular formulation
US20060182781A1 (en) * 2004-04-30 2006-08-17 Allergan, Inc. Methods for treating ocular conditions with cyclic lipid contraining microparticles
US7893040B2 (en) * 2005-07-22 2011-02-22 Oculis Ehf Cyclodextrin nanotechnology for ophthalmic drug delivery
US20070202186A1 (en) * 2006-02-22 2007-08-30 Iscience Interventional Corporation Apparatus and formulations for suprachoroidal drug delivery
ES2529746T3 (es) * 2007-06-25 2015-02-25 Otsuka Pharmaceutical Co., Ltd. Microesferas con una estructura de núcleo/cáscara
EP2482804A1 (en) * 2009-10-01 2012-08-08 Evonik Degussa Corporation Microparticle compositions and methods for treating age-related macular degeneration
CN101816627B (zh) * 2010-04-16 2012-03-07 浙江大学 一种协同治疗型多物质缓释滴眼剂及制备方法
CN102100663B (zh) * 2011-01-14 2013-04-17 华南理工大学 一种pH敏感型原位凝胶纳米缓释眼药水的制备方法

Also Published As

Publication number Publication date
BR112014017969A2 (es) 2017-06-20
IL265620A (en) 2019-05-30
KR20140114892A (ko) 2014-09-29
KR20220044379A (ko) 2022-04-07
AU2013212583A1 (en) 2014-08-14
NZ627368A (en) 2016-11-25
KR102183727B1 (ko) 2020-11-27
EP2806853B1 (en) 2020-07-08
CN104136006B (zh) 2017-11-24
EP2806853A1 (en) 2014-12-03
KR20200073292A (ko) 2020-06-23
BR112014017969A8 (pt) 2017-07-11
AU2017258895A1 (en) 2017-11-30
CA2861348C (en) 2017-07-04
US20200297650A1 (en) 2020-09-24
US20130189369A1 (en) 2013-07-25
MX2014008857A (es) 2015-07-17
JP2015504098A (ja) 2015-02-05
DK2806853T3 (da) 2020-09-28
KR20230104761A (ko) 2023-07-10
IL265620B (en) 2022-03-01
CA2861348A1 (en) 2013-08-01
AU2017258895B2 (en) 2019-04-18
WO2013112434A1 (en) 2013-08-01
ES2821526T3 (es) 2021-04-26
US20230390212A1 (en) 2023-12-07
KR20200133286A (ko) 2020-11-26
HUE050904T2 (hu) 2021-01-28
CN104136006A (zh) 2014-11-05
HK1204765A1 (en) 2015-12-04
RU2014134420A (ru) 2016-03-20
IL233620A0 (en) 2014-08-31
AU2019204957A1 (en) 2019-07-25
JP6282231B2 (ja) 2018-02-21
RU2672596C2 (ru) 2018-11-16
ZA201405091B (en) 2015-12-23

Similar Documents

Publication Publication Date Title
MX364864B (es) Microesferas o microparticulas biodegradables o bioerosionables de liberacion progresiva suspendidas en una formulacion de farmaco inyectable de formacion de deposito solidificante.
MX352369B (es) Articulo para fumar con material de entrega de liquido.
EP3555296A4 (en) METHODS OF EXOGENOUS DRUG ACTIVATION OF CHEMICAL-INDUCED SIGNALING COMPLEXES EXPRESSED IN MODIFIED CELLS IN VITRO AND IN VIVO
MX2019002575A (es) Microcapsulas biodegradables que contienen material de relleno.
PH12016500691A1 (en) Smoking article with liquid release component
ZA201705792B (en) Methods and biocompatible compositions to achieve sustained drug release in the eye
MX2015012887A (es) Composiciones de un poliortoester y un solvente aprotico.
IL240148A0 (en) Biodegradable and clinically compatible nanoparticles as drug delivery carriers
PH12016501061A1 (en) Smoking article with liquid release component having frangible shell
MX2014000129A (es) Combinaciones de farmacos y su usos en el tratamiento de una condicion de tos.
MX2015000114A (es) Composiciones farmaceuticas disuasivas de abuso de liberacion prolongada.
EP2563338A4 (en) HIGH SHEAR APPLICATION USED FOR DRUG DELIVERY
EP3235512A4 (en) Method using polyethylene glycol to prepare fibroin nano/microspheres, and application of method in controlled drug release
UA108885C2 (uk) Композиція рисперидону для ін'єкційної депо-форми
PH12016500706B1 (en) Smoking article with liquid delivery material
MX2016014622A (es) Sistemas de suministro de medicamentos y metodos de uso relacionados.
MX2016009493A (es) Sistemas trasdermicos restrictivos de abuso y mal uso.
EP2925340B8 (en) Pharmaceutical compositions comprising selective agonists of melanocortin 1 receptor and their use in therapeutic methods
MX2016007534A (es) Composicion de gel de acido hialuronico que tiene durabilidad.
AR086346A1 (es) Proceso para producir un material inorganico particulado
MY179519A (en) Smoking article with tactile liquid release component
MX2013013691A (es) Composicion de liberacion sostenida que contiene peptidos como ingredientes activos.
EP2949723A4 (en) RESIN COMPOSITION, COATED PARTICLES, INJECTION MEANS AND METHOD OF INJECTING AN INJECTION AGENT INTO A FRACTURE
WO2014060443A3 (en) A composite scaffold for use as a tissue engineering implant
PH12015501534B1 (en) Sustained release formulations of lorazepam

Legal Events

Date Code Title Description
FG Grant or registration